| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11910-012-0262-Y |
| P698 | PubMed publication ID | 22437507 |
| P2093 | author name string | Bart Neyns | |
| Bernd Kaina | |||
| Christine Marosi | |||
| Herwig M Strik | |||
| P2860 | cites work | Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles | Q43218101 |
| NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide | Q43245397 | ||
| Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme | Q45163828 | ||
| Predictive impact of MGMT promoter methylation in glioblastoma of the elderly | Q45416568 | ||
| Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report | Q46364938 | ||
| Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas | Q46630773 | ||
| A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. | Q46720231 | ||
| Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma | Q48090038 | ||
| Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study | Q48371882 | ||
| Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. | Q48418407 | ||
| Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine | Q48479768 | ||
| Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs | Q71058150 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| A phase II study of extended low-dose temozolomide in recurrent malignant gliomas | Q28344315 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas | Q30442049 | ||
| Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial | Q32034410 | ||
| Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules | Q33347264 | ||
| Extended-schedule dose-dense temozolomide in refractory gliomas | Q33385736 | ||
| Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial | Q33395957 | ||
| Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery | Q33483488 | ||
| A phase I trial of weekly lomustine in patients with advanced cancer | Q33493359 | ||
| Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide | Q33699572 | ||
| MGMT: its role in cancer aetiology and cancer therapeutics | Q34310201 | ||
| MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents | Q34626127 | ||
| A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma | Q34992535 | ||
| DNA repair in resistance to alkylating anticancer drugs | Q35017573 | ||
| Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma | Q35208736 | ||
| Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). | Q36611825 | ||
| MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma | Q39743920 | ||
| Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach | Q40053895 | ||
| Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas | Q42743277 | ||
| Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. | Q42882364 | ||
| O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma | Q43128475 | ||
| P433 | issue | 3 | |
| P921 | main subject | temozolomide | Q425088 |
| P304 | page(s) | 286-293 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Current Neurology and Neuroscience Reports | Q18206211 |
| P1476 | title | Temozolomide dosing regimens for glioma patients | |
| P478 | volume | 12 |
| Q88030103 | A guide for the analysis of long-term population growth in cancer |
| Q52644558 | An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective. |
| Q64107495 | Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? |
| Q42237770 | Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence |
| Q33920087 | Case Report: Pregnancy in a patient with recurrent glioblastoma |
| Q35920319 | Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients |
| Q38833453 | Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells |
| Q33757933 | Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro |
| Q48763582 | Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells |
| Q35234429 | Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation |
| Q57461797 | Sensitivity of CD3/CD28-stimulated versus non-stimulated lymphocytes to ionizing radiation and genotoxic anticancer drugs: key role of ATM in the differential radiation response |
| Q43092195 | Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways |
| Q36288254 | The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. |
| Q38738437 | The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines |
| Q26863755 | Treating malignant glioma in Chinese patients: update on temozolomide |
Search more.